Wolfgang Schröder

Wolfgang Schröder

Auto-generated profile, based on publicly available information

Wolfgang Schröder

Departments of Medicinal Chemistry, Preclinical Drug Safety, Molecular Pharmacology, Pain Pharmacology, Pharmacokinetics, and Discovery Informatics, Global Drug Discovery, Grünenthal Innovation, Grünenthal GmbH , D-52099 Aachen, Germany

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2000 in European Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
SHStefan Hinterkeuser
Stefan Hinterkeuser
WSWolfgang Schröder
Wolfgang Schröder
GHGerhard Hager
Gerhard Hager
GSGerald Seifert
Gerald Seifert
IBIngmar Blümcke
Ingmar Blümcke
CSChristian Steinhäuser
Christian Steinhäuser

1 June 2014 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
KLKlaus Linz
Klaus Linz
TCThomas Christoph
Thomas Christoph
TTThomas M. Tzschentke
Thomas M. Tzschentke
TKThomas Koch
Thomas Koch
KSKlaus Schiene
Klaus Schiene
SFStefanie Frosch
Stefanie Frosch
Cebranopadol (trans-6′-fluoro-4′,9′-dihydro-N,N-dimethyl-4-phenyl-spiro[cyclohexane-1,1′(3′H)-pyrano[3,4-b]indol]-4-amine) is a novel analgesic nociceptin/orphanin FQ peptide (NOP) and opioid receptor agonist [Ki (nM)/EC50 (nM)/relative efficacy (%): human NOP receptor 0.9/13.0/89; human mu-opioid peptide (MOP) receptor 0.7/1.2/104; human kappa-opioid peptide receptor 2.6/17/67; human delta-opioid peptide receptor 18/110/105]. Cebranopadol exhibits highly potent and efficacious antinociceptive and antihypersensitive effects in several rat models of acute and chronic pain (tail-flick, rheumatoid arthritis, bone cancer, spinal nerve ligation, diabetic neuropathy) with ED50 values of 0.5−5.6 µg/kg after intravenous and 25.1 µg/kg after oral administration. In comparison with selective MOP receptor agonists, cebranopadol was more potent in models of chronic neuropathic than acute nociceptive pain. Cebranopadol’s duration of action is long (up to 7 hours after intravenous 12 µg/kg; >9 hours after oral 55 µg/kg in the rat tail-flick test). The antihypersensitive activity of cebranopadol in the spinal nerve ligation model was partially reversed by pretreatment with the selective NOP receptor antagonist J-113397[1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one] or the opioid receptor antagonist naloxone, indicating that both NOP and opioid receptor agonism are involved in this activity. Development of analgesic tolerance in the chronic constriction injury model was clearly delayed compared with that from an equianalgesic dose of morphine (complete tolerance on day 26 versus day 11, respectively). Unlike morphine, cebranopadol did not disrupt motor coordination and respiration at doses within and exceeding the analgesic dose range. Cebranopadol, by its combination of agonism at NOP and opioid receptors, affords highly potent and efficacious analgesia in various pain models with a favorable side effect profile.

4 January 1999 in Glia
Verified
Journal Article
Closed access
PDF file
PKP. Kunzelmann
P. Kunzelmann
OTO. Traub
O. Traub
RDR. Dermietzel
R. Dermietzel
KWK. Willecke
K. Willecke
WSW. Schröder
W. Schröder
CSC. Steinhäuser
C. Steinhäuser

25 April 2014 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
WSW Schröder
W Schröder
DLD G Lambert
D G Lambert
MKM C Ko
M C Ko
TKT Koch
T Koch
Despite high sequence similarity betweenNOP(nociceptin/orphaninFQopioid peptide) and opioid receptors, marked differences in endogenous ligand selectivity, signal transduction, phosphorylation, desensitization, internalization and trafficking have been identified; underscoring the evolutionary difference betweenNOPand opioid receptors. Activation ofNOPreceptors affects nociceptive transmission in a site‐specific manner, with antinociceptive effects prevailing after peripheral and spinal activation, and pronociceptive effects after supraspinal activation in rodents. The net effect of systemically administeredNOPreceptor agonists on nociception is proposed to depend on the relative contribution of peripheral, spinal and supraspinal activation, and this may depend on experimental conditions. Functional expression and regulation ofNOPreceptors at peripheral and central sites of the nociceptive pathway exhibits a high degree of plasticity under conditions of neuropathic and inflammatory pain. In rodents, systemically administeredNOPreceptor agonists exerted antihypersensitive effects in models of neuropathic and inflammatory pain. However, they were largely ineffective in acute pain while concomitantly evoking severe motor side effects. In contrast, systemic administration ofNOPreceptor agonists to non‐human primates (NHPs) exerted potent and efficacious antinociception in the absence of motor and sedative side effects. The reason for this species difference with respect to antinociceptive efficacy and tolerability is not clear. Moreover, co‐activation ofNOPand μ‐opioid peptide (MOP) receptors synergistically produced antinociception inNHPs. Hence, both selectiveNOPreceptor as well asNOP/MOPreceptor agonists may hold potential for clinical use as analgesics effective in conditions of acute and chronic pain.

1 June 2000 in Epilepsia
Verified
Journal Article
Open access
PDF file
WSWolfgang Schröder
Wolfgang Schröder
SHStefan Hinterkeuser
Stefan Hinterkeuser
GSGerald Seifert
Gerald Seifert
JSJohannes Schramm
Johannes Schramm
RJRonald Jabs
Ronald Jabs
CSChristian Steinhäuser
Christian Steinhäuser
Summary: Purpose: The specific role of glial cells in epilepsy is still elusive. In this study, functional properties of astrocytes were investigated in acute hippocampal brain slices obtained from surgical specimens of patients with drug‐resistant temporal lobe epilepsy (TLE). Methods: The patch‐clamp technique together with a single‐cell reverse transcription–polymerase chain reaction approach were used to combine functional and molecular analysis in the same individual cell in situ. Results: In patients with Ammon's horn sclerosis, the glial current patterns resembled properties of immature astrocytes in rodent hippocampus. Depolarizing voltage steps activated delayed rectifier and transient K+ currents as well as tetrodotoxin‐sensitive Na+ currents. Hyperpolarizing voltages elicited inward rectifier K+ currents. Comparative recordings were made in astrocytes from patients with lesion‐associated TLE that lacked significant histopathological hippocampal alterations. The inward rectifier K+ current density was significantly smaller in astrocytes from the sclerotic group compared with lesion‐associated TLE patients. Conclusions: During normal development of rodent brain, astroglial inward rectification gradually increases. It thus appears that astrocytes in human sclerotic tissue reexpress an immature current pattern. Reduced astroglial inward rectification in conjunction with seizure‐induced shrinkage of the extracellular space may lead to impaired spatial K+ buffering. This will result in stronger and prolonged depolarization of glial cells and neurons in response to activity‐dependent K+ release and may thus contribute to seizure generation and spread in this particular condition of human TLE.

1 September 2010 in European journal of pain
Verified
Journal Article
Closed access
WSWolfgang Schröder
Wolfgang Schröder
JVJean De Vry
Jean De Vry
TTThomas M. Tzschentke
Thomas M. Tzschentke
UJUlrich Jahnel
Ulrich Jahnel
TCThomas Christoph
Thomas Christoph